Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Bantham, I disagree, there are a significant number of catalysts that could drop literally any day:
New Lab contracts (lots of discussions ongoing)
Lab accreditation
Launch of Laboratory Developed tests (LDT) -starting with Ovarian.
New Partnerships with Med tech
An Investment/stake building by pharma/med tech
Take over
Any one of the above could drop any day now.
Beyond that there will be more studies announced, further FDA submissions, sales into clinical settings etc
Have you listened to the latest presentation ??
Researcher - I said ‘12-15 months minimum’ as I would expect any well run business to raise cash well in advance of the end of the ‘cash runway’.
Of course we all hope that the business will start generating positive cash flow sooner rather than later and remove the need for any further cash raises.
Come on Jolly, just because you’re now temporarily out don’t start with the ‘placement incoming’ nonsense.
Cash burn is quite predictable - main R&D is paid for, add-on companion assay/test development will hopefully be funded by clients/partners, Lab contracts are already profit generating.
There’s no placement required for another 12-15 months minimum.
It’s true, the likes of BG will invest in ‘risk’ assets on the basis that some will fail but the winners will provide returns measured in multiples.
I would still say that their investment is an indication of their ‘conviction’ that AGL will be a winner, albeit with some ‘execution’ risk.
You have to believe you’re backing a winner every time.
Bantham, I still think 3 months is not unreasonable - if they have costed the move already that means they've had 3rd parties involved e.g. lawyers.
I don't see any indication of low credibility for the Angle team other than a few posters on internet forums - where credibility is pretty scarce.
Baille gifford were happy to invest at 80p recently, that suggests to me that they believe in the team.
Bantham, correct me if I'm wrong but are you suggesting that 3 months is far too long for a business to react to a change in the tax rules ? They have assessed, made a decision, planned/quantified it and now announced what is a fairly significant move to move an R&D centre between countries ?
Is it not also fair to say that the exchange rate moves very recently may have been a deciding factor ?
Cash runway to H2 24 sounds good to me - cash burn should be relatively predictable if they are successful in getting partners to fund development costs - and they have already shown they can do this.
If they need to raise more cash in 2 years time without significant commercial traction then we are in trouble. That's the risk we take here.
This is ridiculously cheap and getting cheaper.... imo of course
Just looked at the trades - it’s all buys and some big ones. I’m always wary of trying to draw conclusions from the trade reporting, it can be distorted and misleading, but it may well suggest that there is a significant seller - the reporting of which will inevitably be delayed.
I’m not concerned if there is - there’s clearly a lot of buyers soaking it up. The seller may be forced/distressed but the buyers are not.
I’m not sure the Jeffries report has helped - I think some people may have looked at their timelines and are thinking it’s going to be slow progress to commercialisation.
But it’s pretty obvious that this is not about AGL - the current investing environment is as bad as it’s been for a very, very long time. Virtually all growth stocks are getting hammered, way more than the main index. It’s horrible but I’ve been investing a long time and I’ve learned to sit tight. There will be huge gains for those who call the bottom of the market and pick up some of the screaming bargains around but it’s a braver man than I who would call it just yet.
Flatlander, I couldn’t read your article (I don’t ‘log-in’) but what you write below confused me:
You are aware that ctDNA is not the same as intact CTCs ? I.E. Angle are not capturing circulating tumour DNA (fragments of dead rumour cells/dna) they are capturing living, whole circulating tumour cells. Different thing and potentially more useful in many ways.
I doubt it but somebody is definitely continuing to buy. The SP was 600p just over a year ago - one bad year due to supply chain issues, which will ease over time, and you could pick these up for a tenth of that price until fairly recently.
I’d say there’s a decent chance of getting back to 200p quite quickly and much more if we get to see real progress being made by the new team.
The deals not done til the cash is in the bank.
It’s overwhelmingly likely at this stage but it could still fall through, stranger things have happened
As for whether it’s in the SP already ? How many of you have bought the rumour and are waiting to sell on the news ?
Goinglarge - the players likely to bid for Angle will have a better understanding of the product and it’s numerous potential applications than any of us here and whether they bid or not will not depend on Angle generating sales in the very short term - which, it seems, is where your focus is.
I don’t think AN actually has any intention of selling - certainly not yet. The potential is huge and I think he wants to build a much bigger business before cashing out.
Conifer are on record as looking for 10x and they bought in at around 65p.
Baille Gifford buying at 80p will be looking for a multiple surely ?
There is still execution risk attached to this and so the big Funds wouldn’t be investing unless they anticipated big enough returns to reward that risk.
But if you were looking for that quick profit then you should have sold on FDA approval.
Mr Sky, I’m not vouching for him, I’ve no idea about him other than what I’ve read today. Just calling out some of the unjustified BS.
I agree with a previous poster - the appointment will have the blessing of the major shareholders, all of whom are American.
In the meantime, the traders will trade but I’m not impacted by the volatility.
Time will tell and I’m happy to wait.
It might be that East gets all the good news out before he goes - if you don’t like the new guy there may well be opportunities to exit before the end of the year.